WallStSmart

Cardinal Health Inc (CAH)vsHong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 1532529% more annual revenue ($250.74B vs $16.36M). CAH leads profitability with a 0.6% profit margin vs -4.3%. CAH earns a higher WallStSmart Score of 47/100 (D+).

CAH

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 4.0Quality: 7.0
Piotroski: 4/9Altman Z: 4.30

HKPD

Avoid

27

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHSignificantly Overvalued (-29.9%)

Margin of Safety

-29.9%

Fair Value

$170.73

Current Price

$201.77

$31.04 premium

UndervaluedFair: $170.73Overvalued

Intrinsic value data unavailable for HKPD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH4 strengths · Avg: 9.3/10
Debt/EquityHealth
-3.1510/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Market CapQuality
$52.43B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

HKPD2 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.8410/10

Safe zone — low bankruptcy risk

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
34.1x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

HKPD4 concerns · Avg: 2.8/10
Market CapQuality
$9.28M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Debt/Equity, Altman Z-Score, Market Cap. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book, Altman Z-Score.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Operating Margin, Piotroski F-Score.

Key Dynamics to Monitor

CAH profiles as a value stock while HKPD is a turnaround play — different risk/reward profiles.

CAH is growing revenue faster at 11.0% — sustainability is the question.

CAH generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CAH scores higher overall (47/100 vs 27/100) and 11.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.

Want to dig deeper into these stocks?